1.3EUR
12.83 MEUR
100.20 MEUR
3.12 M
About PHARMANUTRA
Sector
CEO
Andrea Lacorte
Headquarters
Pisa
Website
Employees (FY)
105
Founded
2003
ISIN
IT0005274094
FIGI
BBG00H5FW2L0
Pharmanutra SpA develops nutraceutical products and medical devices. Its Sroscaloidal Iron intends to restore articular and movement ability in osteoarticular affections, consisting of cetilar line. The company was founded by Andrea Lacorte and Roberto Lacorte in 2003 and is headquartered in Pisa, Italy.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PHN is 53.30 EUR — it has decreased by 0.19% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange PHARMANUTRA stocks are traded under the ticker PHN.
PHARMANUTRA is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for PHARMANUTRA has a max estimate of 86.00 EUR and a min estimate of 77.00 EUR.
PHN earnings for the last quarter are 0.23 EUR whereas the estimation was 0.23 EUR which accounts for 0% surprise. Estimated earnings for the next quarter are 0.40 EUR. See more details about PHARMANUTRA earnings.
PHARMANUTRA revenue for the last quarter amounts to 22.50 M EUR despite the estimated figure of 22.50 M EUR. In the next quarter revenue is expected to reach 26.50 M EUR.
Yes, you can track PHARMANUTRA financials in yearly and quarterly reports right on TradingView.
Like other stocks, PHN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMANUTRA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 105.00 employees. See our rating of the largest employees — is PHARMANUTRA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMANUTRA EBITDA is 22.52 M EUR, and current EBITDA margin is 24.80%. See more stats in PHARMANUTRA financial statements.